Use of specified tcf target genes to identify drugs for the treatment of cancer in particular colorectal cancer in which tcf/ss-cateini/wnt signalling plays a central role

TY - PAT

T1 - Use of specified tcf target genes to identify drugs for the treatment of cancer in particular colorectal cancer in which tcf/ss-cateini/wnt signalling plays a central role

AU - Colland, F.

AU - Barker, N.

AU - Clevers, J.C.

AU - Gomez, E.

AU - Lambertus, M.

AU - Suils, E.S.

N1 - United States Patent 20060165699; http://www.freepatentsonline.com/20060165699.html

PY - 2006

Y1 - 2006

N2 - The present invention relates to the use of inhibitors of the expressed proteins of TCF target genes whose expression is regulated by TCF/.beta.-catenin complexes for the preparation of a therapeutical composition for the treatment of cancers in which TCF/.beta.-catenin signalling is deregulated. Such inhibitors can be antibodies, small molecules, antisense RNA and dsRNA for use in RNAi. The invention also relates to these inhibitors per se.

AB - The present invention relates to the use of inhibitors of the expressed proteins of TCF target genes whose expression is regulated by TCF/.beta.-catenin complexes for the preparation of a therapeutical composition for the treatment of cancers in which TCF/.beta.-catenin signalling is deregulated. Such inhibitors can be antibodies, small molecules, antisense RNA and dsRNA for use in RNAi. The invention also relates to these inhibitors per se.

M3 - Patent

ER -